188 related articles for article (PubMed ID: 11795455)
1. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine.
Rossini PM; Pasqualetti P; Pozzilli C; Grasso MG; Millefiorini E; Graceffa A; Carlesimo GA; Zibellini G; Caltagirone C
Mult Scler; 2001 Dec; 7(6):354-8. PubMed ID: 11795455
[TBL] [Abstract][Full Text] [Related]
2. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
[TBL] [Abstract][Full Text] [Related]
3. The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS.
Morrow SA; Rosehart H; Johnson AM
Mult Scler Relat Disord; 2017 Jan; 11():4-9. PubMed ID: 28104253
[TBL] [Abstract][Full Text] [Related]
4. The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.
Bever CT; Young D; Anderson PA; Krumholz A; Conway K; Leslie J; Eddington N; Plaisance KI; Panitch HS; Dhib-Jalbut S
Neurology; 1994 Jun; 44(6):1054-9. PubMed ID: 8208399
[TBL] [Abstract][Full Text] [Related]
5. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
6. 4-Aminopyridine in multiple sclerosis: prolonged administration.
Stefoski D; Davis FA; Fitzsimmons WE; Luskin SS; Rush J; Parkhurst GW
Neurology; 1991 Sep; 41(9):1344-8. PubMed ID: 1891078
[TBL] [Abstract][Full Text] [Related]
7. Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis.
Marion S; Leonid C; Belinda B; Joanne D; Elise H; Leeanne C; Richard M
Mult Scler Relat Disord; 2020 May; 40():101971. PubMed ID: 32062444
[TBL] [Abstract][Full Text] [Related]
8. Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment.
Romani A; Bergamaschi R; Candeloro E; Alfonsi E; Callieco R; Cosi V
Mult Scler; 2004 Aug; 10(4):462-8. PubMed ID: 15327047
[TBL] [Abstract][Full Text] [Related]
9. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study.
van Diemen HA; Polman CH; van Dongen TM; van Loenen AC; Nauta JJ; Taphoorn MJ; van Walbeek HK; Koetsier JC
Ann Neurol; 1992 Aug; 32(2):123-30. PubMed ID: 1510353
[TBL] [Abstract][Full Text] [Related]
10. A double-blind pilot study of the effect of Prokarin on fatigue in multiple sclerosis.
Gillson G; Richard TL; Smith RB; Wright JV
Mult Scler; 2002 Feb; 8(1):30-5. PubMed ID: 11936486
[TBL] [Abstract][Full Text] [Related]
11. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study.
van Diemen HA; Polman CH; van Dongen MM; Nauta JJ; Strijers RL; van Loenen AC; Bertelsmann FW; Koetsier JC
J Neurol Sci; 1993 Jun; 116(2):220-6. PubMed ID: 8336169
[TBL] [Abstract][Full Text] [Related]
12. Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: Randomized, double-blind, placebo-controlled clinical trial. Preliminary report.
Arreola-Mora C; Silva-Pereyra J; Fernández T; Paredes-Cruz M; Bertado-Cortés B; Grijalva I
Mult Scler Relat Disord; 2019 Feb; 28():117-124. PubMed ID: 30593980
[TBL] [Abstract][Full Text] [Related]
13. Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury: a double-blinded, placebo-controlled crossover trial.
Wolfe DL; Hayes KC; Hsieh JT; Potter PJ
J Neurotrauma; 2001 Aug; 18(8):757-71. PubMed ID: 11526982
[TBL] [Abstract][Full Text] [Related]
14. Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis.
Schwid SR; Petrie MD; McDermott MP; Tierney DS; Mason DH; Goodman AD
Neurology; 1997 Apr; 48(4):817-21. PubMed ID: 9109861
[TBL] [Abstract][Full Text] [Related]
15. The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study.
Smits RC; Emmen HH; Bertelsmann FW; Kulig BM; van Loenen AC; Polman CH
Neurology; 1994 Sep; 44(9):1701-5. PubMed ID: 7936300
[TBL] [Abstract][Full Text] [Related]
16. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety.
Van Diemen HA; Polman CH; Koetsier JC; Van Loenen AC; Nauta JJ; Bertelsmann FW
Clin Neuropharmacol; 1993 Jun; 16(3):195-204. PubMed ID: 8504436
[TBL] [Abstract][Full Text] [Related]
17. The effect of Ginkgo biloba on functional measures in multiple sclerosis: a pilot randomized controlled trial.
Johnson SK; Diamond BJ; Rausch S; Kaufman M; Shiflett SC; Graves L
Explore (NY); 2006 Jan; 2(1):19-24. PubMed ID: 16781604
[TBL] [Abstract][Full Text] [Related]
18. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis.
Wingerchuk DM; Benarroch EE; O'Brien PC; Keegan BM; Lucchinetti CF; Noseworthy JH; Weinshenker BG; Rodriguez M
Neurology; 2005 Apr; 64(7):1267-9. PubMed ID: 15824361
[TBL] [Abstract][Full Text] [Related]
19. Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years.
Broicher SD; Filli L; Geisseler O; Germann N; Zörner B; Brugger P; Linnebank M
J Neurol; 2018 May; 265(5):1016-1025. PubMed ID: 29464379
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Conte A; Bettolo CM; Onesti E; Frasca V; Iacovelli E; Gilio F; Giacomelli E; Gabriele M; Aragona M; Tomassini V; Pantano P; Pozzilli C; Inghilleri M
Eur J Pain; 2009 May; 13(5):472-7. PubMed ID: 18603457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
